These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 30452012)
1. Venous Flare Reactions: A Case Report of Reactions Following Etoposide Infusion. Mini Gill J; Frost J; Park R; Saria MG Clin J Oncol Nurs; 2018 Dec; 22(6):597-599. PubMed ID: 30452012 [TBL] [Abstract][Full Text] [Related]
2. Risks and mitigation strategies to prevent etoposide infusion-related reactions in children. Tillman EM; Suppes SL; Miles N; Duty AM; Kelley KL; Goldman JL Pharmacotherapy; 2021 Aug; 41(8):700-706. PubMed ID: 34129705 [TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to carboplatin in children. Schiavetti A; Varrasso G; Maurizi P; Castello MA Med Pediatr Oncol; 1999 Mar; 32(3):183-5. PubMed ID: 10064185 [TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity reactions to etoposide phosphate. Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. Collier K; Schink C; Young AM; How K; Seckl M; Savage P J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441 [TBL] [Abstract][Full Text] [Related]
6. Association between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide. Ronsley R; Jacques L; Potts JE; Clement K; Dix DB; Mahon P Pediatr Hematol Oncol; 2021 Apr; 38(3):208-215. PubMed ID: 33150845 [TBL] [Abstract][Full Text] [Related]
7. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy. Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778 [TBL] [Abstract][Full Text] [Related]
8. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Siderov J; Prasad P; De Boer R; Desai J Br J Cancer; 2002 Jan; 86(1):12-3. PubMed ID: 11857004 [TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185 [TBL] [Abstract][Full Text] [Related]
10. [Intraarterial chemotherapy using a combination of etoposide and cisplatin for recurrent malignant lymphoma]. Hirayama A; Nakagawa H; Maeda N; Tsuzuki T; Yamamoto H; Kadota T Gan To Kagaku Ryoho; 1998 Nov; 25(13):2135-40. PubMed ID: 9838920 [TBL] [Abstract][Full Text] [Related]
11. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide. Bernstein BJ; Troner MB Pharmacotherapy; 1999 Aug; 19(8):989-91. PubMed ID: 10453971 [TBL] [Abstract][Full Text] [Related]
12. [Successful treatment with etoposide by oral administration for recurrence of gastric diffuse large B-cell lymphoma after surgical resection--a case report]. Fukushima T; Sawaki T; Shimoyama K; Karasawa H; Masaki Y; Kawabata H; Ogawa N; Wano Y; Hirose Y; Sugai S; Sutoh H; Itoh H; Kojima Y Gan To Kagaku Ryoho; 2005 Feb; 32(2):251-3. PubMed ID: 15751644 [TBL] [Abstract][Full Text] [Related]
13. Comparison of local reactions to oxaliplatin infusions by peripheral versus central venous administration. To YY; Sutcliffe KJ; Hoen HM; Swaney RA; Nicholls JD; Crocenzi TS J Oncol Pharm Pract; 2016 Apr; 22(2):256-60. PubMed ID: 25762052 [TBL] [Abstract][Full Text] [Related]
14. Managing Chemotherapy Side Effects: Achieving Reliable and Equitable Outcomes. Beaver CC; Magnan MA Clin J Oncol Nurs; 2016 Dec; 20(6):589-591. PubMed ID: 27857268 [TBL] [Abstract][Full Text] [Related]
15. Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy. Timoney JP; Eagan MM; Sklarin NT J Nurs Care Qual; 2003; 18(1):80-6. PubMed ID: 12518842 [TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma]. Maruyama D Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242 [No Abstract] [Full Text] [Related]
18. An infusion reaction to cetuximab. Waxman ES Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):38-41. PubMed ID: 25391206 [No Abstract] [Full Text] [Related]
20. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]